BioLine Rx (XTAE:BLRX) Net Margin % : -289.25% (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is BioLine Rx Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. BioLine Rx's Net Income for the three months ended in Dec. 2023 was ₪-52.15 Mil. BioLine Rx's Revenue for the three months ended in Dec. 2023 was ₪18.03 Mil. Therefore, BioLine Rx's net margin for the quarter that ended in Dec. 2023 was -289.25%.

The historical rank and industry rank for BioLine Rx's Net Margin % or its related term are showing as below:

XTAE:BLRX' s Net Margin % Range Over the Past 10 Years
Min: -1262.81 Med: -1262.81 Max: -1262.81
Current: -1262.81

XTAE:BLRX's Net Margin % is ranked worse than
75.46% of 1027 companies
in the Biotechnology industry
Industry Median: -160.92 vs XTAE:BLRX: -1262.81

BioLine Rx Net Margin % Historical Data

The historical data trend for BioLine Rx's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx Net Margin % Chart

BioLine Rx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

Get a 7-Day Free Trial

-1,262.80

BioLine Rx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Net Margin %	Get a 7-Day Free Trial															-	-	-	-	-289.25

Competitive Comparison of BioLine Rx's Net Margin %

For the Biotechnology subindustry, BioLine Rx's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioLine Rx's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's Net Margin % distribution charts can be found below:

* The bar in red indicates where BioLine Rx's Net Margin % falls into.

BioLine Rx Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

BioLine Rx's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-227.657	/	18.028
	=	-1,262.80 %

BioLine Rx's Net Margin for the quarter that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-52.146	/	18.028
	=	-289.25 %

BioLine Rx (XTAE:BLRX) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

BioLine Rx Net Margin % Related Terms

Thank you for viewing the detailed overview of BioLine Rx's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLine Rx (XTAE:BLRX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (XTAE:BLRX) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

BLRX:USA YP2A:Germany

Address

2 HaMa’ayan Street, Modi’in, ISR, 7177871

Website

https://www.biolinerx.com

BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.